TheEdgeResearch
Home / Stocks / WGS

GeneDx Holdings Corp. (WGS)

NASDAQ Healthcare Medical - Diagnostics & Research
$88.40 ▼ -0.09%
Market Cap
$2.64B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
2.01
52-Wk Range
32.21-170.87
CEO
Katherine A. Stueland
Country
US
Currency
USD

GeneDx Holdings Corp. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Stamford, CT, US. The stock last traded at $88.40, down 0.09% on the session, giving a market capitalisation of $2.64B. On trailing twelve-month figures it carries a trailing P/E of -24.29, a net margin of -23.4%. Its beta of 2.01 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-24.29
Price / Sales
5.80
Price / Book
10.75
EV / EBITDA
-35.89
Gross margin
68.2%
Operating margin
-13.3%
Net margin
-23.4%
Return on equity
—
Debt / equity
0.69
Current ratio
3.30
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
1,300
IPO date
2020-11-04
Headquarters
Stamford, CT, US
About GeneDx Holdings Corp.

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Comparable companies

GeneDx Holdings Corp. is most often compared with the following Healthcare names:

CRNXHNGEIMVTKYMRNAMSOPCHOSCRPRVATMDXVKTX
More research on WGS
WGS technical analysis WGS TheEdge Score Compare against peers
Open full interactive analysis & DCF →